Agenus Inc.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, re.

businesswire.com - 2026-07-17 10:28:00

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

zacks.com - 2026-07-14 13:01:15

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com - 2026-07-14 09:16:03

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript

seekingalpha.com - 2026-07-13 15:10:22

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants.

proactiveinvestors.com - 2026-07-13 13:11:59

Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-oncology company unveiled an $85 million private placement that could grow to $340 million if investors fully exercise accompanying warrants.

benzinga.com - 2026-07-13 10:28:42

Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer.

marketbeat.com - 2026-07-13 10:02:52

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to...

proactiveinvestors.com - 2026-07-13 08:53:00

VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and powered-shell data center infrastructure has earned it...

proactiveinvestors.com - 2026-07-13 07:00:00

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and L.

businesswire.com - 2026-07-13 06:00:00

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society fo.

businesswire.com - 2026-07-06 07:30:00

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study

gurufocus.com - 2026-06-25 08:00:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases will be presented at the European Society for Medical Oncology Gastrointestinal C.

businesswire.com - 2026-06-25 07:00:00

Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while working to strengthen its financial position and pursue regulatory pathways in the United States and Europe.

marketbeat.com - 2026-06-16 12:08:14

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-10 12:31:16

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.

zacks.com - 2026-06-05 15:05:33

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

zacks.com - 2026-06-05 15:02:03

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.

zacks.com - 2026-06-05 14:55:34

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2026 and enter the 16-digit control number found in their proxy mate.

businesswire.com - 2026-06-02 16:30:00

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

zacks.com - 2026-05-28 11:50:34

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.

zacks.com - 2026-05-26 13:35:52

Agenus: Weighing The Clinical Progress Against The Company's Cash

seekingalpha.com - 2026-05-26 07:25:30

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ASCO2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus' multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, including patients previously treated with anti-CTLA-4 therapy. The full dataset wi.

businesswire.com - 2026-05-21 17:00:00

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology images in patients treated with botensilimab (BOT) plus balstilimab (BAL), Agenus' investigational next-generation multifunctional, Fc-enhanced anti-CTLA-4 and anti.

businesswire.com - 2026-05-21 17:00:00

Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.

zacks.com - 2026-05-21 14:21:06

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in patients with treatment-refractory hepatocellular carcinoma (HCC) who had progressed following prior immunotherapy. The manuscript, titled “A phase 1b study of botensilimab and balstilimab in treatment-refractory h.

businesswire.com - 2026-05-15 16:11:00

Agenus (AGEN) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.1 per share. This compares to a loss of $1.03 per share a year ago.

zacks.com - 2026-05-11 21:06:16

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab plus balstilimab (BOT+BAL), the Company's lead clinical program and one of the most clinically advanced next-generation CTLA-4/PD-1 combinations in development. The first quarter marked a transition from foundation-building to execution for BOT+BAL. Physician engageme.

businesswire.com - 2026-05-11 08:45:00

Here is how Agenus (AGEN) and Align Technology (ALGN) have performed compared to their sector so far this year.

zacks.com - 2026-05-06 10:41:23

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026. Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program. About.

businesswire.com - 2026-05-04 16:30:00

Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-05-04 11:00:18

TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.

zacks.com - 2026-04-29 11:07:11

VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.

zacks.com - 2026-04-28 13:36:08

HSIC heads into Q1 earnings results with steady estimates, a 5.1% revenue growth outlook and strength across distribution, specialty products and tech.

zacks.com - 2026-04-28 09:31:22

CI approaches Q1 results with strong pharmacy growth but a steep premium drop, as estimates point to mixed year-over-year performance.

zacks.com - 2026-04-27 12:26:09

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-04-23 10:52:24

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab (BOT), alone or in combination with balstilimab (BAL), have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago, Illinois. The accepted abstracts reflect continued progress of Agenus' botensilimab and balstilimab immunotherapy program ac.

businesswire.com - 2026-04-21 10:00:00

LEXINGTON, Mass. & MARLOW, England--(BUSINESS WIRE)---- $AGEN #AAC--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus' global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Ef.

businesswire.com - 2026-04-21 08:00:00

Here is how Agenus (AGEN) and Apyx Medical (APYX) have performed compared to their sector so far this year.

zacks.com - 2026-04-20 10:42:56